Kalaris Therapeutics, Inc. KLRS
2.05 USD +0.05 (+2.50%)
At close·Nov 3, 2026, 4:02 PM EST
2.05 0.00 0.00%
After hours · Nov 3, 4:02 PM ET
- YTD
- -75.71%
- 1 year
- -58.92%
Altman Z-Score
-2.38 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
0 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B3 / 5 overall
- DCF 5
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 4
P/E -3.0×
P/S 0.0×
P/B 1.6×
P/FCF -3.0×
EV/EBITDA -0.8×
EV/Sales 0.0×
FCF Yield -33.5%
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
ROE -55.1%
ROIC -41.1%
ROA -35.7%
Revenue 0.0%
Operating Income 16.5%
EPS (diluted) 75.7%
Free Cash Flow 36.2%
Current Ratio 12.2×
Quick Ratio 12.2×
Debt / Equity 0.0×
Net Debt / EBITDA 2.3×
Interest Coverage -32.0×
Dividend Yield 0.0%
Payout Ratio 0.0%
Annual · latest fiscal year ends 2025-12-31
